All In Biotech

Drug Trial Radar · NCT07197554

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

171

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
SEED Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

Conditions

  • Advanced Solid Tumors
  • Ewing Sarcoma
  • Hepatocellular Carcinoma (HCC)
  • Biliary Tract Cancer (BTC)

Interventions

  • ST-01156Drug

    ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Dose EscalationTime frame: First 28 days of treatment
  2. Part 1: Dose EscalationTime frame: Duration of treatment period

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The City of Hope National Medical Center

    Duarte, California · Recruiting

  • Hoag Memorial Hospital

    Newport Beach, California · Recruiting

  • Mass General Brigham Cancer Institute

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.